Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

NCT03563222 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Prematurely stopped in agreement with authorities (FDA)

Conditions

Malnutrition, Child

Interventions

DRUG: Smoflipid
DRUG: Intralipid, 20%

Sponsor

Fresenius Kabi